Official UK procurement notice
CLI-VEA-57525 BREAST CANCER ARTIFICIAL INTELLIGENCE
Authority: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) (Central government)
What is being bought
Published requirement descriptionUtilising AI to support Pathologists in assessing and quantitating tumour markers when reporting breast cancer biopsies.
CPV: Software package and information systems
The lotProcurement structure
single lot · no lot value publishedLot #1Utilising AI to support pathologists in the review of the slides, in identifying,…Awarded
Utilising AI to support pathologists in the review of the slides, in identifying, grading and characterizing suspected findings of cancer in breast biopsy specimens and in filling slide- and case-level reports.
The application also supports the pre-ordering of Breast tumour biomarkers based on the detection and characterization of Invasive breast cancer.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 16 Oct 2024, 14:17 BST
- Last source update
- 28 Oct 2024, 10:16 GMT
- Authority reference
CLI-VEA-57525- FTS notice number
2024/S 000-034807- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-04acd7Find a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
A successful pilot in BCUHB is utilising AI to support Pathologists in assessing and quantitating tumour markers when reporting breast cancer biopsies. It is proposed to utilise additional funding awarded from Welsh Government to roll out this development to all Health Boards.
Publisher note: (WA Ref:145595)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Ibex Medical Analytics LtdSME | £163,448 †same award published again · counted once | — | Awarded |
| Ibex Medical Analytics LtdSME | £163,448 † | — | Awarded |
Contracts
Contract 033379-2024-CLI-VEA-57525-1 · Ibex Medical Analytics LtdSME
- Signed
- 16 Oct 2024
- Value
- £163,448
- Status
- active
Contract 034807-2024-CLI-VEA-57525-1 · Ibex Medical Analytics LtdSME
- Signed
- 16 Oct 2024
- Value
- £163,448
- Status
- active
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 1bids · 1 electronic · 1 from abroad | 1 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- High CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- Ibex Medical Analytics LtdAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.